HLM006474
SIGMA/SML1260 - ≥98% (HPLC)
Synonym: 7-
CAS Number: 353519-63-8
Empirical Formula (Hill Notation): C25H25N3O2
Molecular Weight: 399.48
MDL Number: MFCD02168344
Linear Formula: C25H25N3O2
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white to beige |
| form | powder |
| InChI | 1S/C25H25N3O2/c1-4-30-21- |
| InChI key | CYNZBLNMIJNBSF-UHFFFAOYSA |
| Quality Level | 100  |
| SMILES string | CC1=CC(C(NC2=NC=CC=C2)C3= |
| solubility | DMSO: 5 mg/mL, clear (warmed) |
| storage temp. | 2-8°C |
| Application: | HLM006474 has been used as an E2 factor (E2F) inhibitor in human nasopharyngeal carcinoma hone-1 cells and T. annulata-infected TBL20 cells. |
| Biochem/physiol Actions: | HLM006474 activates p53 and induces DNA damage and apoptosis in mouse tumor models. |
| Biochem/physiol Actions: | HLM006474 is a pan-E2F transcription factor inhibitor. |
| Biochem/physiol Actions: | HLM006474 is a pan-E2F transcription factor inhibitor. E2F s part of the CDK/Rb/E2F pathway. When phosphorylated by CDKs, the tumor suppressor retinoblastoma protein (Rb) is inactivated, releasing E2Fs and allowing cell cycle progression. HLM006474 inhibited DNA-binding of all E2F complexes and down-regulated expression of E2F4 protein. HLM006474 induced apoptosis of A375 melanoma cells and synergized with paclitaxel in lung cancer cell lines. |
| Packaging: | 5, 25 mg in glass bottle |
| Symbol |  GHS07 |
| Signal word | Warning |
| Hazard statements | H302 - H413 |
| Precautionary statements | P301 + P312 + P330 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |